Article Correctness Is Author's Responsibility: The benefits & dangers when genetic testing companies partner with orphan drug developers

(Mary Ann Liebert, Inc./Genetic Engineering News) Pharmaceutical companies developing Orphan Drugs are increasingly partnering with direct-to-consumer (DTC) genetic testing firms to identify individuals with rare diseases, in a trend that is raising concerns related to privacy, drug costs, and rising healthcare-related financial burden for consumers.
Posted in Uncategorized